ASCO-GI – Jazz sees a new Ziihera Herizon
But Tevimbra’s role looks shaky as adverse events loom.
Instil’s bispecific dream is over
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
FDA red and green lights: December 2025
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
Incyte does TGF-beta differently
Four months after yielding first-in-human data INCA33890 enters phase 3.
Another in vivo Car speeds into the clinic
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
Christmas oncology roundup
The holiday period included Genmab’s discontinuation of acasunlimab.
GSK makes haste while Daiichi struggles
Mocertatug rezetecan is starting its first western pivotal trials.
